Claims:

1. (Original) A compound of formula (I)



(I)

wherein:

R^1 is H or CH_3;

R^2 is C_1-C_2 alkyl; and

n is 1 or 2;

a tautomer thereof or a pharmaceutically acceptable salt, or solvate of said compound or tautomer.

2. (Original) The compound according to Claim 1 wherein n is 1.

3. (Original) The compound according to Claim 1 or Claim 2 wherein R^1 is hydrogen.

4. (Original) The compound according to Claim 3 wherein R^2 is methyl.

5. (Original) The compound according to Claim 3 wherein R^2 is ethyl.

6. (Original) The compound according Claim 1 or Claim 2 wherein R^1 is methyl.

7. (Original) The compound according to Claim 6 wherein R^2 is methyl.

8. (Original) The compound according to Claim 6 wherein R^2 is ethyl.

9. (Original) The compound according to Claims 1 or 2 wherein R^2 is methyl.

10. (Original) The compound according to Claims 1 or 2 wherein R^2 is ethyl.

11. (Original) The compound according to Claim 1 selected from

(*R*)-2-Methyl-3-(1-{[3-(2-methyl-1,3-benzothiazol-6-yl)propyl]carbamoyl} cyclopentyl)propanoic acid;

3-(1-{[3-(2-ethyl-1,3-benzothiazol-6-yl)propyl]carbamoyl}cyclopentyl)propanoic acid;

(*R*)-2-Methyl-3-(1-{[3-(2-ethyl-1,3-benzothiazol-6-yl)propyl]carbamoyl} cyclopentyl)propanoic acid; or

3-(1-{[3-(2-ethyl-1,3-benzothiazol-6-yl)propyl]carbamoyl}cyclohexyl)propanoic acid.

12. (Original) A compound of Formula Ia,



Ia,

a tautomer thereof or a pharmaceutically acceptable salt, or solvate of said compound or tautomer.

13. (Original) A pharmaceutical composition comprising a compound of formula (I) as claimed in any one of Claims 1, 2, 11 or 12, or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutically acceptable diluent or carrier.

14. (Cancelled).

15. (Currently amended) A method of treating or preventing a disorder or condition ~~by inhibiting NEP~~ selected from obesity, female sexual dysfunction (FSD), sexual arousal disorder, female sexual arousal disorder (FSAD), male sexual dysfunction (MSD), male erectile dysfunction (MED), hypoactive sexual desire disorder, orgasmic disorder and sexual pain disorder in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound of formula (I) as claimed in any one of Claims 1, 2, 11 or 12, or a pharmaceutically acceptable salt, or solvate thereof.

16. (Original) The method according to Claim 15 wherein n is 1.

17. (Original) The method according to Claim 15 or Claim 16 wherein R^1 is hydrogen.

18. (Original) The method according to Claim 17 wherein R^2 is methyl.

19. (Original) The method according to Claim 17 wherein R^2 is ethyl.

20. (Original) The method according to Claims 15 or 16 wherein R^1 is methyl.

21. (Original) The method according to Claim 20 wherein R^2 is methyl.

22. (Original) The method according to Claim 22 wherein R^2 is ethyl.

23. (Original) The method according to Claims 15 or 16 wherein R^2 is methyl.

24. (Original) The method according to Claims 15 or 16 wherein R^2 is ethyl.

25. (Cancelled).

26. (Currently Amended) The method according to Claim 15 ~~25~~ wherein the disorder or condition is selected from female sexual dysfunction (FSD), sexual arousal disorder, female sexual arousal disorder (FSAD), male sexual dysfunction (MSD), male

erectile dysfunction (MED), hypoactive sexual desire disorder, orgasmic disorder and sexual pain disorder.

27. (Original) The method according to Claim 26 wherein the disorder or condition is selected from female sexual dysfunction (FSD), female sexual arousal disorder (FSAD), male sexual dysfunction (MSD), and male erectile dysfunction (MED).

28-33. (Cancelled).